Homeopathic Medicines in COVID-19: Prognostic Factor Research

Background: Data collection studies were conducted during COVID-19 pandemic to identify useful homeopathic medicines with their prescribing indications.

Methods: Only confirmed COVID-19 cases with mild to moderate disease were treated with homeopathy as an add on to the standard conventional treatment. The data of ~2,500 patients were analyzed retrospectively using prognostic factor research model. The data collection was challenging and could be made possible by training and Government’s support.

Results: Six papers have been published, and a 7^th is under consideration. Initially, the symptomatology of COVID-19 was catalogued. Then the prescribing indications of Bry, Ars, Gels, and Puls found useful in the 1^st wave were identified. Biases noticed during data collection and their implications on big data were deliberated. A comparison between Indian and a LMHI database reflected a strong consensus. The indications of medicines found useful during the 2^nd wave i.e., Bell, Hep-s, Phos, Rhus-t and Merc-s were identified. An algorithm on COVID-19 was tested (English: https://hpra.co.uk/). Our next publication is on the 3^rd wave data, wherein the indications of Nux-v are added.

Conclusion: The real-time practice-based data using prognostic factor research can help in improving the existing repertories, success rate of practice, and can contribute to case repositories such as CliFiCol (www.clificol.net), VithoulkasCompass (www.vithoulkascompass.com), and HCCR (hccr.ccrhindia.in).

Keywords: COVID-19, homeopathy, prognostic factor research

Publication History

Article published online:
30 January 2024